Drugs / Vasopressin
Vasopressin
also known as
arginine vasopressin · AVP · argipressin · Pitressin · Vasostrict · Arg · D-arginine-D-vasopressin · Empressin · +2 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | VASOSTRICT | — | 2014-04-17 | fda.gov ↗ |
Trials 69 · started per year
today
US approved 2014
1
2
1
3
5
1
2
3
1
1
3
2
4
6
4
4
2
1
4
11
3
5
20002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT04463394 | Aug 2020 → Feb 2022 | Fontan-associated liver disease, hypotensive disorder | Stanford University | Completed | No outcome recorded |
| Phase 0 | NCT02993640 | Sep 2016 → Mar 2017 | portal hypertension | Sahlgrenska University Hospital | Completed | No outcome recorded |
| Phase 0 | NCT02394054 | Jan 2015 → Jul 2016 | — | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 0 | NCT01680718 | Oct 2012 → Sep 2013 | — | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 0 | NCT00420407 | Feb 2007 → Apr 2009 | — | The University of Texas Health Science Center at San Antonio | Terminated | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT05738148 | Nov 2023 → Jan 2026 overdue | cardiac arrest | University of Alberta | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04093050 | Oct 2019 → Apr 2021 | — | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 1 | NCT01327027 | Sep 2011 → Dec 2015 | — | Bowdoin College | Completed | No outcome recorded |
| Phase 1 | NCT01093768 | Feb 2010 → Apr 2013 | autism spectrum disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 1 | NCT00628550 | Apr 2008 → Oct 2010 | cardiac arrest | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03446456 | Sep 2018 → Sep 2026 expected | — | University of Maryland, Baltimore | Recruiting | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT07614438 | Aug 2026 overdue | chronic thromboembolic pulmonary hypertension | Fondation Hôpital Saint-Joseph | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06547892 | Apr → Oct 2025 overdue | — | Hospital do Coracao | Recruiting | No outcome recorded |
| Phase 2 | NCT05958342 | Jun 2024 → Mar 2027 expected | hemorrhagic disease | Jason Sperry | Recruiting | No outcome recorded |
| Phase 2 | NCT03191240 | Dec 2017 → Aug 2021 | cardiac arrest | Asan Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01370096 | Feb 2012 → Sep 2016 | pulmonary hypertension | University of Alberta | Terminated | No outcome recorded |
| Phase 2 | NCT00481572 | Jan → Dec 2007 | infectious disease with sepsis | University of Roma La Sapienza | Completed | No outcome recorded |
| Phase 2 | NCT00411879 | Jun 2006 → Apr 2007 | cardiac arrest | University of Athens | Completed | No outcome recorded |
| Phase 2/37 trials | ||||||
| Phase 2/3 | NCT03483753 | Jan 2019 → Oct 2023 | — | University of Sao Paulo | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT03640949 | Sep 2018 → Jan 2021 | cardiac arrest | Lars Wiuff Andersen | Completed | No outcome recorded |
| Phase 2/3 | NCT03204786 | Feb 2018 → Mar 2024 | autism | Stanford University | Completed | No outcome recorded |
| Phase 2/3 | NCT03088345 | Mar 2017 → Nov 2018 | congenital heart disease, univentricular heart, vascular insufficiency disorder | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 2/3 | NCT02975999 | Dec 2016 → Dec 2019 | univentricular heart | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT00995839 | Nov 2008 → Feb 2010 | infectious disease with sepsis | University of Roma La Sapienza | Completed | No outcome recorded |
| Phase 2/3 | NCT00269685 | Jul 2000 → ? | — | University of Sherbrooke | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT07063680 | Apr 2026 → Jan 2029 expected | — | Centre Hospitalier Universitaire Dijon | Recruiting | No outcome recorded |
| Phase 3 | NCT07423156 | Mar → Aug 2026 overdue | placenta praevia | Allama Iqbal Medical College | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07052084 | Jan 2026 → Feb 2028 expected | infectious disease with sepsis | Assistance Publique Hopitaux De Marseille | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06344442 | Apr → May 2025 overdue | acute kidney injury | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT06464510 | Nov 2024 → Aug 2027 expected | infectious disease with sepsis | Hospital do Coracao | Recruiting | No outcome recorded |
| Phase 3 | NCT05568160 | Jan 2023 → Mar 2026 overdue | — | Centre Hospitalier Universitaire Dijon | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00729794 | Sep 2008 → Nov 2010 | cardiac arrest | University of Athens | Completed | No outcome recorded |
| Phase 415 trials | ||||||
| Phase 4 | NCT07633600 | Jun 2026 → Jun 2027 expected | — | Jennifer Cutler | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06709573 | Apr 2025 → May 2026 overdue | infectious disease with sepsis | The Cleveland Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT06419075 | Jul 2024 → Jan 2025 | pelvic organ prolapse | The University of Texas Medical Branch, Galveston | Withdrawn | No outcome recorded |
| Phase 4 | NCT06471231 | May 2024 → May 2026 | impaired renal function disease, infectious disease with sepsis | Azienda Usl di Bologna | Unknown | No outcome recorded |
| Phase 4 | NCT06934798 | Apr 2024 → Jul 2025 overdue | arterial disorder | University of Sao Paulo | Recruiting | No outcome recorded |
| Phase 4 | NCT06290596 | Apr → Oct 2024 | uterine disorder | Al-Azhar University | Unknown | No outcome recorded |
| Phase 4 | NCT06265259 | Dec 2023 → Dec 2025 | — | University of Thessaly | Unknown | No outcome recorded |
| Phase 4 | NCT05886192 | May 2023 → Jan 2025 | infectious disease with sepsis | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05293041 | Mar 2022 → Dec 2024 | inflammatory disease, metastasis from malignant tumor of colon | Kristina Svennerholm | Completed | No outcome recorded |
| Phase 4 | NCT04935814 | Jun 2021 → Aug 2022 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 4 | NCT04602767 | Oct 2020 → May 2024 | acute kidney injury | Thomas Jefferson University | Unknown | No outcome recorded |
| Phase 4 | NCT03815344 | Apr 2017 → Jun 2019 | leiomyoma | Antonios Likourezos | Completed | No outcome recorded |
| Phase 4 | NCT05439460 | Jan 2012 → Jun 2014 | pulmonary arterial hypertension | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT00127907 | May 2004 → Oct 2007 | cardiac arrest | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 4 | NCT00799292 | Jan 2004 → Jan 2005 | — | Ascher-Walsh, Charles, M.D. | Completed | No outcome recorded |
| Phase not applicable22 trials | ||||||
| — | NCT06605300 | Oct 2024 → Jul 2025 | — | University of Electronic Science and Technology of China | Completed | No outcome recorded |
| — | NCT06203847 | Jul 2024 → Jul 2026 overdue | cardiac arrest | National Taiwan University Hospital | Recruiting | No outcome recorded |
| — | NCT06329063 | Mar 2024 → Jun 2025 | — | University of Electronic Science and Technology of China | Unknown | No outcome recorded |
| — | NCT06329037 | Mar 2024 → Jun 2025 | — | University of Electronic Science and Technology of China | Unknown | No outcome recorded |
| — | NCT06234592 | Jan 2024 → Jan 2026 overdue | acute kidney injury, infectious disease with sepsis | King's College Hospital NHS Trust | Recruiting | No outcome recorded |
| — | NCT04890470 | Mar 2021 → Dec 2022 | — | University of Electronic Science and Technology of China | Completed | No outcome recorded |
| — | NCT04493554 | Jul → Nov 2020 | — | University of Electronic Science and Technology of China | Completed | No outcome recorded |
| — | NCT04214145 | Jan 2020 → Sep 2021 | — | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT04170751 | Nov 2019 → Sep 2021 | essential hypertension | Yonsei University | Unknown | No outcome recorded |
| — | NCT04053478 | Jul 2019 → Dec 2026 expected | hypotensive disorder | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Recruiting | No outcome recorded |
| — | NCT03725553 | Dec 2018 → Jun 2021 | placenta praevia | Aswan University Hospital | Completed | No outcome recorded |
| — | NCT03590873 | Jul 2018 → Jun 2019 | — | Hangang Sacred Heart Hospital | Unknown | No outcome recorded |
| — | NCT04190004 | Jan → Nov 2018 | schizophrenia | National Institute of Mental Health and Neuro Sciences, India | Completed | No outcome recorded |
| — | NCT04715737 | Dec 2017 → Jan 2021 | — | University of Electronic Science and Technology of China | Completed | No outcome recorded |
| — | NCT02526914 | Oct 2015 → Jul 2017 | — | Hadassah Medical Organization | Unknown | No outcome recorded |
| — | NCT02377492 | Mar 2015 → Mar 2017 | leiomyoma | University Hospitals Cleveland Medical Center | Withdrawn | No outcome recorded |
| — | NCT02223429 | Aug 2014 → Feb 2016 | — | James K. Rilling, PhD | Completed | No outcome recorded |
| — | NCT01800877 | Apr 2013 → Dec 2014 | hypotensive disorder | Francois Lamontagne | Completed | No outcome recorded |
| — | NCT01296269 | Apr 2011 → May 2012 | — | Hadassah Medical Organization | Unknown | No outcome recorded |
| — | NCT02053675 | May 2008 → Apr 2013 | infectious disease with sepsis | Federal University of São Paulo | Completed | No outcome recorded |
| — | NCT01566539 | Apr 2008 → Nov 2016 | — | Emory University | Completed | No outcome recorded |
| — | NCT00886262 | Jul 2007 → Aug 2011 | liver failure | Medical University of South Carolina | Completed | No outcome recorded |
Also used as a comparator or background therapy in 35 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 26 trials | ||||||
| Phase 2 | NCT06302998 Comparator | Jun 2024 → Dec 2025 | infectious disease with sepsis | Mansoura University | Unknown | No outcome recorded |
| Phase 2 | NCT07446933 Comparator | Mar 2024 → Oct 2025 | — | Zagazig University | Completed | No outcome recorded |
| Phase 2 | NCT01962870 Comparator | Dec 2013 → May 2017 | autism spectrum disorder | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT01611935 Comparator | May 2013 → Sep 2016 | — | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT01247090 Comparator | Oct 2010 → Aug 2018 | end stage renal failure, hypertensive disorder | Columbia University | Completed | No outcome recorded |
| Phase 2 | NCT00624650 Background | Feb 2008 → Jan 2011 | acute lung injury | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT03930069 Comparator | May 2016 → Jan 2017 | submucous uterine fibroid | Zagazig University | Completed | No outcome recorded |
| Phase 2/3 | NCT00379522 Comparator | Jul 2010 → Oct 2014 | — | Volker Wenzel | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT05139849 Comparator | Nov 2021 → Jan 2027 expected | post-cardiac arrest syndrome | Tiohundra AB | Recruiting | No outcome recorded |
| Phase 3 | NCT04501861 Comparator | Nov 2020 → Aug 2023 | heart disorder | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 3 | NCT03636451 Background | Oct 2018 → Dec 2020 | uterine disorder | University of California, San Diego | Completed | No outcome recorded |
| Phase 3 | NCT01861015 Comparator | May 2013 → Mar 2014 | leiomyoma | CHA University | Completed | No outcome recorded |
| Phase 3 | NCT01718613 Comparator | Nov 2012 → Mar 2014 | infectious disease with sepsis | Cancer Institute of the State of São Paulo | Completed | No outcome recorded |
| Phase 3 | NCT01505231 Comparator | Jan 2012 → Feb 2013 | — | University of Sao Paulo | Unknown | No outcome recorded |
| Phase 3 | NCT00358579 Comparator | Mar 2006 → Jan 2009 | cardiac arrest | Singapore General Hospital | Completed | No outcome recorded |
| Phase 49 trials | ||||||
| Phase 4 | NCT07102615 Comparator | Oct 2025 → Aug 2026 overdue | — | Prisma Health-Upstate | Recruiting | No outcome recorded |
| Phase 4 | NCT06217562 Comparator | Feb 2024 → Jul 2026 overdue | infectious disease with sepsis | Intermountain Health Care, Inc. | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05193370 Comparator | Jan → Nov 2022 | infectious disease with sepsis | University of New Mexico | Withdrawn | No outcome recorded |
| Phase 4 | NCT03317197 Comparator | Jan 2018 → Aug 2020 | cardiac arrest | Korea University Guro Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02675868 Comparator | Jan → Jul 2016 | — | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02454348 Comparator | Nov 2015 → Nov 2017 | — | University of Arkansas | Withdrawn | No outcome recorded |
| Phase 4 | NCT02118467 Comparator | May 2014 → Oct 2026 expected | — | University of Chicago | Recruiting | No outcome recorded |
| Phase 4 | NCT01393704 Comparator | Jul 2011 → Apr 2015 | — | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01700478 Background | Feb → Apr 2005 | hemorrhagic disease | University Hospital of the West Indies | Completed | No outcome recorded |
| Phase not applicable11 trials | ||||||
| — | NCT05920707 Comparator | Apr → Sep 2023 | — | University of Electronic Science and Technology of China | Unknown | No outcome recorded |
| — | NCT06125184 Comparator | Nov 2022 → Oct 2024 | acute kidney injury, heart failure | Pontificia Universidad Catolica de Chile | Unknown | No outcome recorded |
| — | NCT05315557 Comparator | Apr 2022 → Mar 2023 | cirrhosis of liver, infectious disease with sepsis | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| — | NCT04874246 Comparator | May → Dec 2021 | leiomyoma | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT03880045 Comparator | Apr 2019 → Mar 2021 | leiomyoma | Aswan University Hospital | Unknown | No outcome recorded |
| — | NCT04302584 Comparator | Jan 2018 → Jan 2019 | acute kidney injury, infectious disease with sepsis | Ain Shams University | Completed | No outcome recorded |
| — | NCT02726620 Background | Jan → Dec 2017 | hypotensive disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT01493102 Comparator | Dec 2011 → Dec 2013 | infectious disease with sepsis | Samsung Medical Center | Terminated | No outcome recorded |
| — | NCT01318278 Comparator | Mar 2011 → Jan 2013 | hypotensive disorder | Baylor College of Medicine | Completed | No outcome recorded |
| — | NCT00795366 Comparator | Sep 2008 → Sep 2014 | traumatic brain injury | University of Miami | Completed | No outcome recorded |
| — | NCT00816751 Background | Dec 2007 → Feb 2008 | — | University of California, San Diego | Completed | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 111 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vasopressin | “Injection of Vasopressin into the uterine tissue surrounding fibroids constricts blood vessels, and has been found to be beneficial by decreasing blood flow to fibroids, and...” NCT03815344 ↗94“Mean arterial pressure (MAP) will be increased from 65 mmHg to 85 mmHg with a blind drug (Vasopressin at 0.03 IU/min). If MAP does not increase norepinephrine will be titrated...” NCT06125184 ↗ “The investigators will use vasopressin as the primary vasopressor and a heart rate-calibrated dexmedetomidine infusion in septic shock patients.” NCT06302998 ↗ “Arginine vasopressin (AVP), an essential stress hormone released in response to hypotension” NCT06344442 ↗ “Using Vasopressin \[20 IU/CPR cycle\] injection until the 5th cycle” NCT03317197 ↗ “Vasostrict® (vasopressin injection, USP)” NCT04093050 ↗ “vasopressin (Pitressin® 20Unints/vial)” NCT06203847 ↗ “vasopressin” NCT06709573 ↗ “vasopressin” NCT01800877 ↗ “Vasopressin” NCT07633600 ↗ |
| Known as | Arg | “Arg” NCT05293041 ↗ |
| Known as | arginine vasopressin | “Adult in-patients with cardiac arrest not responsive to two direct current countershocks (when applicable) or asystole or pulseless electrical activity are randomized to...” NCT00411879 ↗13“Efficacy of Early Argipressin (Arginine Vasopressin) in the Management of Intensive Care Patients With Norepinephrine-refractory Vasoplegic Shock: a Multicentric Randomized,...” NCT07063680 ↗ “The neuropeptides arginine vasopressin and oxytocin play key roles in socioemotional processes such as pair bonding and parental care” PMID 25462898 ↗ Oct 2014 “Arginine vasopressin (AVP) and related peptides have diverse effects on social behaviors in vertebrates” PMID 29018407 ↗ Sep 2017 “The hormone arginine vasopressin (AVP), in particular, may prove a useful adjunct during resuscitation.” NCT01611935 ↗ |
| Known as | argipressin | “Vasopressin is commercially available under the name "argipressin".” NCT04935814 ↗ |
| Known as | AVP | “The present study was designed to determine the effects of continuously infused norepinephrine (NE) plus (1) terlipressin (TP) or (2) arginine vasopressin (AVP) or (3) placebo...” PMID 21929764 ↗ Sep 201112“The main aim of the present study is to investigate the effects of orally administered vasopressin (AVP) on bottom-up and top-down attentional control to socio-emotional stimuli” NCT06329037 ↗ “Although potential links between oxytocin (OT), vasopressin (AVP), and social cognition are well-grounded theoretically” PMID 37310308 ↗ Oct 2021 “addition of vasopressin (AVP), a drug used as a vasopressor but with cathecholamine independent mechanisms” NCT06125184 ↗ “Arginine vasopressin (AVP) and related peptides have diverse effects on social behaviors in vertebrates” PMID 29018407 ↗ Sep 2017 “The hormone arginine vasopressin (AVP), in particular, may prove a useful adjunct during resuscitation.” NCT01611935 ↗ “Vasopressin (AVP) is commonly added to norepinephrine (NE) to reverse shock in patients with sepsis.” PMID 29784057 ↗ May 2018 “Arginine vasopressin (AVP), an essential stress hormone released in response to hypotension” NCT06344442 ↗ “the neuropeptide oxytocin (OXT) and vassopressin (AVP) influence moral decision making” NCT04890470 ↗ “Oxytocin (OT) and vasopressin (AVP) have been shown to improve social cognition” PMID 27053769 ↗ Apr 2016 “Intranasal Vasopressin (AVP) 40 IU” NCT01566539 ↗ “using arginine vasopressin (AVP)” NCT00795366 ↗ “Intranasal Vasopressin (AVP)” NCT06605300 ↗ |
| Known as | D-arginine-D-vasopressin | “Vasopressin (D-arginine-D-vasopressin) is an endogenous hormone synthesized by the hypothalamus” NCT04935814 ↗ |
| Known as | Empressin | “20 IU of vasopressin (Empressin®, Amomed Pharma GmbH)” NCT03640949 ↗ |
| Known as | Pitressin | “Adult in-patients with cardiac arrest not responsive to two direct current countershocks (when applicable) or asystole or pulseless electrical activity are randomized to...” NCT00411879 ↗1“vasopressin (Pitressin® 20Unints/vial)” NCT06203847 ↗ |
| Known as | Vasopressin (Vasostrict) (Par Pharmaceutical, Chestnut Ridge, NY). | “Vasopressin (Vasostrict) (Par Pharmaceutical, Chestnut Ridge, NY).” NCT06419075 ↗ |
| Known as | Vasopressins | “Drug: Vasopressins” NCT03191240 ↗ |
| Known as | Vasostrict | “Vasopressin (USP) Injectable Solution [Vasostrict]” NCT03204786 ↗1“Vasostrict® (vasopressin injection, USP)” NCT04093050 ↗ |
| Action | Activate | “vasopressin receptor agonists terlipressin and vasopressin” NCT00995839 ↗ |
| Modality | Peptide | “The goal of this protocol, broadly stated, is to evaluate the effects of the neuropeptides oxytocin and vasopressin on the neural systems involved in social cognition and...” NCT01093768 ↗ |
| Route | Intravenous | “intravenous adrenaline (1mg) or vasopressin (40 IU) at ED” PMID 22353644 ↗ Feb 2012 |
| Target | AVPR1A | “binds to AVPR1a to promote vasoconstriction” NCT06344442 ↗ |